Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

The abscopal effect of radiotherapy and nivolumab in relapsed or refractory Hodgkin lymphoma

Dr Paul Bröckelmann - University of Cologne, Cologne, Germany
The abscopal effect of radiotherapy and nivolumab in relapsed or refractory Hodgkin lymphoma ( Dr Paul Bröckelmann - University of Cologne, Cologne, Germany )
13 Jun 2022

Quizartinib improves overall survival in adult patients with FLT3-ITD+ acute myeloid leukaemia

Dr Harry Erba - The Duke Cancer Institue, Durham, USA
Quizartinib improves overall survival in adult patients with FLT3-ITD+ acute myeloid leukaemia ( Dr Harry Erba - The Duke Cancer Institue, Durham, USA )
13 Jun 2022

Adagrasib shows CNS penetration and encouraging intracranial activity for KRASG12C-mutated NSCLC and active, untreated CNS metastases

Dr Joshua Sabari - Perlmutter Cancer Center NYU Langone Health, New York, USA
Adagrasib shows CNS penetration and encouraging intracranial activity for KRASG12C-mutated NSCLC and active, untreated CNS metastases ( Dr Joshua Sabari - Perlmutter Cancer Center NYU Langone Health, New York, USA )
10 Jun 2022

ASCO 2022: Head and neck cancer highlights

Dr Mark Persky - NYU Langone’s Perlmutter Cancer Center, New York, USA
ASCO 2022: Head and neck cancer highlights ( Dr Mark Persky - NYU Langone’s Perlmutter Cancer Center, New York, USA )
10 Jun 2022

Comment: LUMINA results show that women with low levels of the Ki67 biomarker can avoid outcomes related to radiotherapy

Dr Corey Wayne Speers - University of Michigan, Ann Arbor, USA
Comment: LUMINA results show that women with low levels of the Ki67 biomarker can avoid outcomes related to radiotherapy ( Dr Corey Wayne Speers - University of Michigan, Ann Arbor, USA )
9 Jun 2022

Biomarker guidance allows patients 55 or older with low-grade luminal A-type breast cancer to avoid radiation therapy

Dr Timothy J. Whelan - McMaster University, Ontario, Canada
Biomarker guidance allows patients 55 or older with low-grade luminal A-type breast cancer to avoid radiation therapy ( Dr Timothy J. Whelan - McMaster University, Ontario, Canada )
9 Jun 2022

Comment: Biomarker guidance allows patients 55 or older with low-grade luminal A-type breast cancer to avoid radiation therapy

Dr Bishal Gyawali - Queen's University, Kingston, Canada
Comment: Biomarker guidance allows patients 55 or older with low-grade luminal A-type breast cancer to avoid radiation therapy ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )
7 Jun 2022

Momelotinib superior to danazol in symptomatic and anaemic myelofibrosis patients previously treated with a JAK inhibitor

Dr Ruben A. Mesa - UT Health San Antonio MD Anderson Cancer Center, San Antonio, USA
Momelotinib superior to danazol in symptomatic and anaemic myelofibrosis patients previously treated with a JAK inhibitor ( Dr Ruben A. Mesa - UT Health San Antonio MD Anderson Cancer Center, San Antonio, USA )
7 Jun 2022

Pembrolizumab demonstrates clinically meaningful improvement in distant metastasis-free survival in patients with melanoma

Dr Georgina Long - The University of Sydney, Sydney, Australia
Pembrolizumab demonstrates clinically meaningful improvement in distant metastasis-free survival in patients with melanoma ( Dr Georgina Long - The University of Sydney, Sydney, Australia )
6 Jun 2022

Elacestrant significantly prolongs PFS for ER+/HER2- metastatic breast cancer without prior chemotherapy patients

Dr Virginia G. Kaklamani - UT Health San Antonio MD Anderson Cancer Center, San Antonio, USA
Elacestrant significantly prolongs PFS for ER+/HER2- metastatic breast cancer without prior chemotherapy patients ( Dr Virginia G. Kaklamani - UT Health San Antonio MD Anderson Cancer Center, San Antonio, USA )
6 Jun 2022

ASCO 2022: Breast cancer highlights

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy
ASCO 2022: Breast cancer highlights ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )
6 Jun 2022

ASCO 2022: Latest in prostate cancer, including PARP inhibitors

Dr Neal Shore, Prof Cora Sternberg, Prof Eleni Efstathiou and Prof Phil Cornford
ASCO 2022: Latest in prostate cancer, including PARP inhibitors ( Dr Neal Shore, Prof Cora Sternberg, Prof Eleni Efstathiou and Prof Phil Cornford )
6 Jun 2022